Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
0.5 - 1 μg/mL |
2.5 μg/mL |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
Human Brain Tissue Slide(GTX22203) , Human Colon Tissue Lysate(GTX27928)
Product Note
This antibody is specific for Plxdc2 C-Terminus
Form
Liquid
Buffer
PBS
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Plxdc2 antibody was raised against a 17 amino acid synthetic peptide from near the carboxy terminus of human Plxdc2.The immunogen is located within the last 50 amino acids of Plxdc2.
Purification
Purified by antigen-affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
plexin domain containing 2 , TEM7R
Cellular Localization
Membrane
Background
Plxdc2, also known as Tumor endothelial marker 7-related (TEM7R) encodes a protein with 57% amino acid identity to TEM7, the most abundant tumor endothelial marker. Plxdc2 is strongly expressed in the endothelial cells of the tumor stroma, but not in the endothelial cells of normal colonic tissue. Plxdc2 is also expressed at high levels in vessels of some normal tissues, with highest expression in muscle and lung. Plxdc2 and TEM7 may be important for tumor angiogenesis in humans. Cortactin was identified as a protein capable of binding to the extracellular region of both TEM7 and Plxdc2, and may provide new opportunities for the delivery of therapeutic and imaging agents to the vessels of solid tumors.
Database
Research Area